290 related articles for article (PubMed ID: 22129845)
1. Proteomics technologies for biomarker discovery in multiple sclerosis.
Singh V; Hintzen RQ; Luider TM; Stoop MP
J Neuroimmunol; 2012 Jul; 248(1-2):40-7. PubMed ID: 22129845
[TBL] [Abstract][Full Text] [Related]
2. New technologies for biomarker discovery in multiple sclerosis.
Comabella M; Racke MK
J Neuroimmunol; 2012 Jul; 248(1-2):1. PubMed ID: 22726889
[No Abstract] [Full Text] [Related]
3. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
Dagley LF; Emili A; Purcell AW
Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
Ekegren T; Hanrieder J; Bergquist J
J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
[TBL] [Abstract][Full Text] [Related]
5. Application of LC/MS to proteomics studies: current status and future prospects.
Chen G; Pramanik BN
Drug Discov Today; 2009 May; 14(9-10):465-71. PubMed ID: 19429505
[TBL] [Abstract][Full Text] [Related]
6. From bench to MS bedside: challenges translating biomarker discovery to clinical practice.
Rajasekharan S; Bar-Or A;
J Neuroimmunol; 2012 Jul; 248(1-2):66-72. PubMed ID: 22381245
[TBL] [Abstract][Full Text] [Related]
7. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application.
Mischak H; Delles C; Klein J; Schanstra JP
Adv Chronic Kidney Dis; 2010 Nov; 17(6):493-506. PubMed ID: 21044772
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of urinary proteomics/peptidomics.
Albalat A; Mischak H; Mullen W
Expert Rev Proteomics; 2011 Oct; 8(5):615-29. PubMed ID: 21999832
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in mass spectrometry-based peptidome analysis.
Hu L; Ye M; Zou H
Expert Rev Proteomics; 2009 Aug; 6(4):433-47. PubMed ID: 19681678
[TBL] [Abstract][Full Text] [Related]
10. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis.
Villoslada P; Baranzini S
J Neuroimmunol; 2012 Jul; 248(1-2):58-65. PubMed ID: 22281286
[TBL] [Abstract][Full Text] [Related]
11. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
Bharti A; Ma PC; Salgia R
Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
[TBL] [Abstract][Full Text] [Related]
12. The discovery and validation of colorectal cancer biomarkers.
Ang CS; Phung J; Nice EC
Biomed Chromatogr; 2011 Jan; 25(1-2):82-99. PubMed ID: 21058408
[TBL] [Abstract][Full Text] [Related]
13. Industrialized MS-based proteomics in the search for circulating biomarkers.
Migneault I; Hunter JM
Bioanalysis; 2009 Sep; 1(6):1149-63. PubMed ID: 21083081
[TBL] [Abstract][Full Text] [Related]
14. CE-MS in biomarker discovery, validation, and clinical application.
Mischak H; Schanstra JP
Proteomics Clin Appl; 2011 Feb; 5(1-2):9-23. PubMed ID: 21280234
[TBL] [Abstract][Full Text] [Related]
15. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
Calvo KR; Liotta LA; Petricoin EF
Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
[TBL] [Abstract][Full Text] [Related]
16. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder.
Ziemann U; Wahl M; Hattingen E; Tumani H
Prog Neurobiol; 2011 Dec; 95(4):670-85. PubMed ID: 21524682
[TBL] [Abstract][Full Text] [Related]
17. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
18. Ten years of proteomics in multiple sclerosis.
Farias AS; Pradella F; Schmitt A; Santos LM; Martins-de-Souza D
Proteomics; 2014 Mar; 14(4-5):467-80. PubMed ID: 24339438
[TBL] [Abstract][Full Text] [Related]
19. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
Findeisen P; Neumaier M
Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
[TBL] [Abstract][Full Text] [Related]
20. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
Fredolini C; Liotta LA; Petricoin EF
Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
